Type
|
Kommanditgesellschaft auf Aktien with Aktiengesellschaft as partner with unlimited liability |
---|---|
Traded as | FWB: FME NYSE: FMS |
Industry | Health care |
Founded | 1996 |
Headquarters | Bad Homburg, Germany |
Key people
|
Rice Powell (CEO and Chairman of the executive board), Michael Brosnan (CFO), Roberto Fusté (Chief Executive Officer for Asia-Pacific), Dr. Emanuele Gatti (Chief Executive Officer for Europe, Middle East, Africa and Latin America), Ronald Kuerbitz (Chief Executive Officer for North America), Gerd Krick (Chairman of the supervisory board) |
Products | Kidney dialysis products and services, Therapuetic Aphoresis Products |
Revenue | US $14.6 billion (2013) |
Operating income
|
US $2,256 million (2013) |
Profit | US $1,110 million (2013) |
Total assets | US $22.120 billion (end 2013) |
Total equity | US $9.485 billion (end 2013) |
Number of employees
|
90,690 (FTE, end 2013) |
Website | www.freseniusmedicalcare.com |
Fresenius Medical Care is a German company specializing in the production of medical supplies, primarily to facilitate or aid renal dialysis. It is 30% owned by the health care company Fresenius. As of December 31, 2015, the number of Fresenius Medical Care shares held by its largest shareholder, Fresenius SE & Co. KGaA remained unchanged at around 94.4 M. This corresponds to a 30.9% interest in its share capital.
Fresenius Medical Care operates more than 40 production sites on all continents. Its largest plants in terms of production output are in the U.S. (Ogden, Utah, and Concord, California), Germany (Schweinfurt and St. Wendel), and Japan (Buzen). These plants are categorized as large and small with 25 large facilities and 15 small ones worldwide which cater to local demand for dialysis products. Plants that fall under the concentrates division, manufacture finished products from raw materials, such as sodium chloride, dextrose, and magnesium, to name a few. Raw materials go through a complex mixing and packaging process.
Fresenius Medical Care manufactures a variety of durable medical devices used in the treatment of End Stage Renal Disease (ESRD). Devices include Hemodialysis Machines, Peritoneal Dialysis Machines, Granuflo Concentrate Mixing Tanks and monitoring devices including the Crit-line device. The dialysis machines are manufactured in one of two plants to serve the globe. These plants are located in Schweinfurt, Germany and Concord, California. Crit-line devices are manufactured in Concord, California.
Distribution is where the finished product, from Manufacturing, comes in on Semi-Trucks to be distributed to dialysis clinics, hospitals, and home dialysis patients. These products are then used in the dialysis process.
On 30 October 2006, the manufacturing facility (Fresenius Hemocare) in Redmond, Washington was shut down. Fresenius Hemocare has stopped going by the name Fresenius Hemocare and now goes by the name Fresenius-Kabi LLC. The closing of one of two entities inside of Hemocare allowed for the name change and takes Hemocare from the Medical Care group to the Kabi group.
In 2012, Fresenius acquired Liberty Dialysis Holdings, in a deal which entailed the sale of its outpatient dialysis clinics in 43 local markets within the U.S.
In 2013, Fresenius Medical Care NA acquired Shiel Medical Laboratory Inc, expanding services to New York City metro area.
Fresenius Medical Care Renal Services Limited runs 54 dialysis units across England and more across Wales. In September 2014 new renal dialysis units run by Fresenius were opened at Withybush General Hospital and West Wales General Hospital, with a contract to run for at least 7 years.
In August 2017, Fresenius acquired NxStage Medical, a medical device manufacturer based in Lawrence, Massachusetts for a reported $2 billion dollars.
Period | Date | Adjusted Actuals EPS | GAAP EPS |
---|---|---|---|
Q3 2022 | 2022-11-01 | Future report Set alerts | |
Q2 2022 | 2022-08-02 | Future report Set alerts | |
Q1 2022 | 2022-05-04 | 0.34 | 0.34 |
Q4 2021 | 2022-02-22 | 0.00 | 0.00 |
Q3 2021 | 2021-11-02 | 0.00 | 0.00 |
Q2 2021 | 2021-07-30 | 0.38 | 0.38 |
Q1 2021 | 2021-05-06 | 0.00 | 0.00 |
Q4 2020 | 2021-02-23 | 0.64 | 0.64 |
Q3 2020 | 2020-10-29 | 0.00 | 0.00 |
Q2 2020 | 2020-07-30 | 0.60 | 0.68 |
2016-07-08 | Upgrade | Jefferies Group | Underperform to Hold | |
2016-05-24 | Reiterated Rating | RBC Capital | Hold | |
2016-05-24 | Reiterated Rating | Royal Bank Of Canada | Hold | |
2016-05-16 | Reiterated Rating | Robert W. Baird | Hold | |
2016-05-10 | Reiterated Rating | DZ Bank AG | Sell | |
2016-04-11 | Initiated Coverage | Sanford C. Bernstein | Outperform | |
2016-03-17 | Initiated Coverage | Nomura | Buy | |
2016-03-17 | Initiated Coverage | Nomura Holdings Inc. | Buy | |
2016-03-04 | Reiterated Rating | DZ Bank AG | Sell | |
2016-02-13 | Upgrade | Berenberg Bank | Buy | |
2016-01-26 | Reiterated Rating | Nord/LB | Buy | |
2016-01-04 | Upgrade | JPMorgan Chase & Co. | Neutral to Overweight | |
2015-11-24 | Reiterated Rating | Goldman Sachs | Buy | |
2015-11-24 | Reiterated Rating | Goldman Sachs Group Inc. | Buy | |
2015-11-09 | Downgrade | Barclays | Equal Weight to Underweight | |
2015-11-09 | Downgrade | Barclays PLC | Equal Weight to Underweight | |
2015-11-04 | Boost Price Target | RBC Capital | Sector Perform | $40.00 to $42.00 |
2015-10-30 | Reiterated Rating | Piper Jaffray | Hold | $41.00 to $43.00 |
2015-10-30 | Reiterated Rating | Piper Jaffray Cos. | Hold | $41.00 to $43.00 |
2015-10-29 | Reiterated Rating | DZ Bank AG | Sell | |
2015-09-22 | Reiterated Rating | Goldman Sachs | Buy | |
2015-09-15 | Reiterated Rating | Goldman Sachs | Buy | |
2015-09-03 | Upgrade | Goldman Sachs | Neutral to Buy | |
2015-08-13 | Downgrade | Societe Generale | Buy to Hold | |
2015-07-31 | Boost Price Target | RBC Capital | Sector Perform | $35.00 to $40.00 |
2015-05-29 | Downgrade | Commerzbank AG | Hold | |
2015-02-27 | Upgrade | HSBC | Underweight to Neutral | |
2015-01-21 | Downgrade | Barclays | Overweight to Equal Weight | |
2014-12-18 | Downgrade | Bryan Garnier & Cie | Neutral | |
2014-12-18 | Downgrade | Bryan, Garnier & Co | Neutral | |
2014-12-15 | Initiated Coverage | Dundee Securities | Buy | |
2014-11-28 | Downgrade | Morgan Stanley | Overweight to Equal Weight | |
2014-10-24 | Upgrade | Berenberg Bank | Hold to Buy | |
2014-10-10 | Upgrade | Bank of America | Neutral to Buy | |
2014-10-10 | Upgrade | Bank of America Corp. | Neutral to Buy | |
2014-09-16 | Boost Price Target | Sanford C. Bernstein | $40.50 to $42.20 | |
2014-08-11 | Upgrade | Societe Generale | Hold to Buy | |
2014-08-01 | Boost Price Target | Piper Jaffray | $33.00 to $34.00 | |
2014-06-30 | Downgrade | Jefferies Group | Hold to Underperform | |
2014-06-26 | Upgrade | Credit Suisse | Neutral to Outperform | |
2014-05-12 | Lower Price Target | Piper Jaffray | $34.00 to $33.00 | |
2014-03-05 | Downgrade | Berenberg Bank | Buy to Hold | |
2014-03-04 | Downgrade | HSBC | Neutral to Underweight | |
2014-01-08 | Upgrade | JPMorgan Chase & Co. | Underweight to Neutral | |
2013-12-02 | Upgrade | Morgan Stanley | Equal Weight to Overweight | |
2013-09-27 | Downgrade | Deutsche Bank | Hold to Sell | $44.00 |
2013-01-14 | Upgrade | HSBC Securities | Neutral to Overweight | |
2012-10-11 | Downgrade | HSBC Securities | Overweight to Neutral | |
2012-08-02 | Downgrade | HSBC Securities | Overweight to Neutral | |
2010-02-25 | Downgrade | Piper Jaffray | Overweight to Neutral | |
2010-02-09 | Initiated | Jefferies & Co | Buy | |
2009-08-19 | Initiated | Stifel Nicolaus | Hold | $44 |
2009-06-25 | Initiated | Sun Trust Rbsn Humphrey | Buy | $51 |
2009-04-16 | Reiterated | RBC Capital Mkts | Outperform | $59 to $56 |
2008-11-17 | Downgrade | Deutsche Securities | Buy to Hold | |
2008-10-13 | Upgrade | UBS | Neutral to Buy | |
2008-07-11 | Downgrade | Wachovia | Outperform to Mkt Perform |
2016-07-08 | Upgrade | Jefferies Group | Underperform to Hold | |
2016-05-24 | Reiterated Rating | RBC Capital | Hold | |
2016-05-24 | Reiterated Rating | Royal Bank Of Canada | Hold | |
2016-05-16 | Reiterated Rating | Robert W. Baird | Hold | |
2016-05-10 | Reiterated Rating | DZ Bank AG | Sell |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In FMS 119 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
PZENA INVESTMENT MANAGEMENT LLC | 13.12M |
FIDUCIARY MANAGEMENT INC /WI/ | 6.11M |
Invesco Ltd. | 1.37M |
DODGE & COX | 1.28M |
CITADEL ADVISORS LLC | 1.19M |
MORGAN STANLEY | 1.05M |
TWEEDY BROWNE CO LLC// | 1.00M |
TWO SIGMA INVESTMENTS LLC | 0.52M |
PARAMETRIC PORTFOLIO ASSOCIATES LLC | 0.48M |
BlackRock Inc. | 0.40M |
TWO SIGMA ADVISERS, LLC | 0.39M |
Marshall Wace LLP | 0.31M |
MANAGED ACCOUNT ADVISORS LLC | 0.30M |
NWQ INVESTMENT MANAGEMENT COMPANY, LLC | 0.24M |
NORTHERN TRUST CORP | 0.20M |